A novel long acting DPP-IV inhibitor PKF-275-055 stimulates beta-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
The enzyme dipeptidyl peptidase-IV (DPP-4) inactivates the incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 has therapeutic effects in patients with type 2 diabetes, but its potential is limited by a short half-life, DPP-4 inhibition is a promising.....